| Treating ALK-positive lung cancer-early successes and future challenges. | |
| | |
MedLine Citation:
|
PMID: 22473102 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in association with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clinical use in this molecularly defined subgroup of lung cancer. Many new ALK inhibitors are being developed and understanding the challenges of determining and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be critical in the future for informing the optimal therapy of ALK+ NSCLC. |
| | |
Authors:
|
D Ross Camidge; Robert C Doebele |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-03 |
Journal Detail:
|
Title: Nature reviews. Clinical oncology Volume: - ISSN: 1759-4782 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500077 Medline TA: Nat Rev Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Anschutz Cancer Pavillion, Mailstop F704, 1665 North Aurora Court, Aurora, CO 80045, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of aspirin in cancer prevention.
Next Document: Molecular prescreening to select patient population in early clinical trials.